image credit: Adobe Stock

FDA’s Office of New Drugs Highlights New Research Projects for Growth

April 18, 2023


In 2018, FDA’s Center for Drug Evaluation and Research’s (CDER’s) Office of New Drugs (OND) developed a research program to centralize and enhance its regulatory science research activities. In more recent years, the OND Research Program (OND-RP) published its first two fiscal year annual reports, and there are important projects that are looking to help improve research outcomes for patient populations.

Read More on Biopharm International